Kolexia
Benisvy Danielle
Médecine nucléaire
Centre Antoine Lacassagne
Nice, France
67 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de la thyroïde Carcinomes Maladies de la thyroïde Tumeurs du poumon Carcinome papillaire Adénocarcinome folliculaire Tumeurs de la parathyroïde Adénomes Cancer papillaire de la thyroïde

Industries

Merck-Serono
2 collaboration(s)
Dernière en 2022
Eisai
2 collaboration(s)
Dernière en 2021
Ipsen
1 collaboration(s)
Dernière en 2023
ADVANCED ACCELERATOR APPLICATIONS
1 collaboration(s)
Dernière en 2023

Dernières activités

Estimabl2 trial: Thyroidectomy without radioiodine in patients with low-risk thyroid cancer, 5 years of follow-up
39e congrès de la Société Française d'Endocrinologie 2023   01 octobre 2023
INTERMEDIATE: Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy
Essai Clinique (Centre François-Baclesse)   06 septembre 2023
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research   06 juillet 2023
ESTIMABL2: Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?
Essai Clinique (Gustave-Roussy)   16 mai 2023
SFE-AFCE-SFMN 2022 Consensus on the management of thyroid nodules : What is the role of functional imaging and isotopic treatment?
Annales d'endocrinologie   21 octobre 2022
Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer.
The New England journal of medicine   23 mars 2022
LENVOS: A Prospective, Multicentre Phase II Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas (LENVOS)
Essai Clinique (Centre Léon-Bérard)   14 mars 2022
Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR.
European journal of cancer (Oxford, England : 1990)   09 septembre 2021
1743MO MERAIODE: A redifferentiation phase II trial with trametinib followed by radioactive iodine for metastatic radioactive iodine refractory differentiated thyroid cancer patients with a RAS mutation
Abstract Book of the ESMO Congress 2021, 16 – 21 September 2021   01 septembre 2021
Comparaison des valeurs pronostiques d’estimateurs de la charge tumorale initiale en TDM et TEP au FDG dans le cadre de l’immunothérapie des cancers pulmonaires
7èmes Journées Francophones de Médecine Nucléaire - Paris   01 juillet 2021